Argenx's Subcutaneous Efgartigimod At Par With Intravenous Administration In Neuromuscular Disorder

Argenx SE ARGX ) has announced topline data from the Phase 3 ADAPT-SC study evaluating subcutaneous (SC) efgartigimod for generalized myasthenia gravis (gMG). 

  • Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles.
  • SC efgartigimod achieved the primary endpoint of total IgG reduction from baseline at day 29, demonstrating statistical noninferiority to Vyvgart (efgartigimod alfa-fcab) intravenous (IV) formulation. 
  • Argenx plans to submit a Biologics License Application (BLA) to the FDA by the end of 2022.
  • SC efgartigimod is co-formulated with recombinant human hyaluronidase PH20 (rHuPH20), Halozyme Therapeutics Inc's HALO ENHANZE drug delivery technology that facilitates subcutaneous injection delivery of biologics that are typically administered via infusion.
  • Related: Argenx's Vyvgart Wins FDA Approval For Autoimmune, Neuromuscular Disease.
  • SC efgartigimod demonstrated a mean total IgG reduction of 66.4% from baseline at day 29, compared to 62.2% with Vyvgart. 
  • Additional key secondary endpoints were met, consistent with clinical efficacy results seen in the Vyvgart Phase 3 ADAPT study, 
  • SC efgartigimod demonstrated a safety profile consistent with the Phase 3 ADAPT study. It was generally well-tolerated.
  • Price Action: ARGX shares are up 3.92% at $310.21 during the market session on the last check Tuesday.
Posted In: BriefsBiotechNewsHealth CareMoversTrading IdeasGeneral